Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.